loading...| Preferred Name | alpha-1-proteinase inhibitor human | |
| Synonyms |
Prolastin-C Aralast A1AT A1P1 AAT alpha-1 antitrypsin alpha-1-antiproteinase alpha 1 antitrypsin |
|
| Definitions |
Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C82258" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82258" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000721983 |
|
| altLabel |
Prolastin-C Aralast A1AT A1P1 AAT alpha-1 antitrypsin alpha-1-antiproteinase alpha 1 antitrypsin |
|
| cui |
C1587957 C2746829 C0795657 |
|
| DATE FIRST PUBLISHED |
2012-01-05 |
|
| Date last modified |
2012-07-23 |
|
| definition |
Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C82258" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82258" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C82258 |
|
| notation |
CDR0000721983 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
alpha-1-proteinase inhibitor human |
|
| tui |
T116 T129 T121 |